Body composition variation and impact of low skeletal muscle mass in patients with advanced medullary thyroid carcinoma treated with vandetanib: Results from a placebo-controlled study

Journal of Clinical Endocrinology and Metabolism

Volumn 98, Issue 6, 2013, Pages 2401-2408

  Massicotte, Marie Hélène ^a,c   Borget, Isabelle ^a   Broutin, Sophie ^a   Baracos, Vickie E ^b   Leboulleux, Sophie ^a   Baudin, Eric ^a   Paci, Angelo ^a   Deroussent, Alain ^a   Schlumberger, Martin ^a   Antoun, Sami ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b UNIVERSITY OF ALBERTA   (Canada)

^c CENTRE HOSPITALIER UNIVERSITAIRE DE SHERBROOKE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; VANDETANIB;

ADIPOSE TISSUE; ADULT; AGED; ARTICLE; BODY COMPOSITION; CLINICAL ARTICLE; CLINICAL TRIAL (TOPIC); COMPUTER ASSISTED TOMOGRAPHY; DISEASE ASSOCIATION; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG WITHDRAWAL; FEMALE; HUMAN; INTRAABDOMINAL FAT; MALE; MUSCLE MASS; PRIORITY JOURNAL; SKELETAL MUSCLE; SUBCUTANEOUS FAT; THYROID MEDULLARY CARCINOMA; UNSPECIFIED SIDE EFFECT; WEIGHT GAIN;

EID: 84878516111     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2013-1115     Document Type: Article

References (27)

1. Chougnet C, Brassard M, Leboulleux S, Baudin E, Schlumberger M. Molecular targeted therapies for patients with refractory thyroid cancer. Clin Oncol (R Coll Radiol). 2010;22:448-455.
2. Kloos RT, Eng C, Evans DB, et al American Thyroid Association Guidelines Task Force. Medullary thyroid cancer: management guidelines of the American thyroid association. Thyroid. 2009;19:565-612.
3. Langmuir PB, Yver A. Vandetanib for the treatment of thyroid cancer. Clin Pharmacol Ther. 2012;91:71-80.
4. Wells SA Jr, Robinson BG, Gagel et al. Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, doubled-blind phase III trial. J Clin Oncol. 2012;30:134-141.
5. Anisimov A, Alitalo A, Korpisalo P, et al. Activated forms of VEGF-C and VEGF-D provide improved vascular function in skeletal muscle. Circ Res. 2009;104:1302-1312.
6. Ledoux S, Queguiner I, Msika S, et al. Angiogenesis associated with visceral and subcutaneous adipose tissue in severe human obesity. Diabetes. 2008;57:3247-3257.
7. Glass DJ. Molecular mechanisms modulating muscle mass. Trends Mol Med. 2003;9:344-350. (Pubitemid 37040030)
8. Arsic N, Zacchigna S, Zentilin L, et al. Vascular endothelial growth factor stimulates skeletal muscle regeneration in vivo. Mol Ther. 2004;10:844-854. (Pubitemid 39419911)
9. Bodine SC, Stitt TN, Gonzalez M, et al. Akt/mTOR pathway is a crucial regulator of skeletal muscle hypertrophy and can prevent muscle atrophy in vivo. Nat Cell Biol. 2001;3:1014-1019. (Pubitemid 34428747)
10. Antoun S, Birdsell L, Sawyer MB, Venner P, Escudier B, Baracos VE. Association of skeletal muscle wasting with treatment with sorafenib in patients with advances renal cell carcinoma: results from a placebo-controlled study. J Clin Oncol. 2010;28:1054-1060.
11. Prado CM, Lieffers JR, McCargar LJ, et al. Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: a population-based study. Lancet Oncol. 2008;9:629-635.
12. Tan BH, Birdsell LA, Martin L, Baracos VE, Fearon KC. Sarcopenia in an overweight or obese patient is an adverse prognostic factor in pancreatic cancer. Clin Cancer Res. 2009;15:6973-6979.
13. Prado CM, Baracos VE, McCargar LJ, et al. Body composition as an independent determinant of 5-fluorouracil-based chemotherapy toxicity. Clin Cancer Res. 2007;13:3264-3268. (Pubitemid 46944911)
14. Prado CM, Baracos VE, McCargar LJ, et al. Sarcopenia as a determinant of chemotherapy toxicity and time to tumor progression in metastatic breast cancer patients receiving capecitabine treatment. Clin Cancer Res. 2009;15:2920-2926.
15. Antoun S, Baracos VE, Birdsell L, Escudier B, Sawyer MB. Low body mass index and sarcopenia associated with dose-limiting toxicity of sorafenib in patients with renal cell carcinoma. Ann Oncol. 2010;21:1594-1598.
16. Mourtzakis M, Prado CM, Lieffers JR, Reiman T, McCargar LJ, Baracos VE. A practical and precise approach to quantification of body composition in cancer patients using computed tomography images acquired during routine care. Appl Physiol Nutr Metab. 2008;33:997-1006.
17. Shen W, Punyanitya M, Wang Z, et al. Total body skeletal muscle and adipose tissue volumes: estimation from a single abdominal cross-sectional image. J Appl Physiol. 2004;97:2333-2338. (Pubitemid 39552474)
18. Mitsiopoulos N, Baumgartner RN, Heymsfield SB, Lyons W, Gallagher D, Ross R. Cadaver validation of skeletal muscle measurement by magnetic resonance imaging and computerized tomography. J Appl Physiol. 1998;85:115-122. (Pubitemid 28334913)
19. Zirrolli JA, Bradshaw EL, Long ME, Gustafson DL. Rapid and sensitive LC/MS/MS analysis of the novel tyrosine kinase inhibitor ZD6474 in mouse plasma and tissues. J Pharm Biomed Anal. 2005;39:705-711. (Pubitemid 41196086)
20. Prado CM, Bekaii-Saab T, Doyle LA, et al. Skeletal muscle anabolism is a side effect of therapy with the MEK inhibitor: selumetinib in patients with cholangiocarcinoma. Br J Cancer. 2012;106:1583-1586.
21. Mayer L, Walsh BT, Pierson RN Jr, et al. Body fat redistribution after weight gain in women with anorexia nervosa. Am J Clin Nutr. 2005;81:1286-1291. (Pubitemid 41710228)
22. Mayer LE, Klein DA, Black E, et al. Adipose tissue distribution after weight restoration and weight maintenance inwomenwith anorexia nervosa. Am J Clin Nutr. 2009;90:1132-1137.
23. Fearon K, Strasser F, Anker SD, et al. Definition and classification of cancer cachexia: an international consensus. Lancet Oncol. 2011;12:489-495.
24. Mir O, Coriat R, Blanchet B, et al. Sarcopenia predicts early doselimiting toxicities and pharmacokinetics of sorafenib in patients with hepatocellular carcinoma. Plos One. 2012;7:e37563.
25. Clinical Pharmacology Review: Vandetanib. U.S. Food and Drug Administration, Center for Drug Evaluation and Research. http://www.accessdata. fda.gov/drugsatfda-docs/nda/2011/022405Orig1s000ClinPharmR.pdf. Accessed November 10, 2012.
26. Delbaldo C, Chatelut E, Ré M, et al. Pharmacokinetic- pharmacodynamic relationships of imatinib and its main metabolite in patients with advanced gastrointestinal stromal tumors. Clin Cancer Res. 2006;12:6073-6078. (Pubitemid 44703771)
27. Widmer N, Decosterd LA, Csajka C, et al. Population pharmacokinetics of imatinib and the role of alpha-acid glycoprotein. Br J Clin Pharmacol. 2006;62:97-112. (Pubitemid 44195246)